colorectal cancer (CRC)

By Targets:	Antibiotic (2) Apoptosis (11) Autophagy (1) Bacterial (1) Bcl-2 Family (1) Carbonic Anhydrase (1) CDK (2) COX (1) CXCR (1) Cytochrome P450 (2) DNA/RNA Synthesis (1) EGFR (1) Endogenous Metabolite (2) ERK (2) Fungal (2) Gli (1) Hedgehog (1) LAG-3 (1) MDM-2/p53 (2) Microtubule/Tubulin (2) NF-κB (3) Parasite (1) PD-1/PD-L1 (2) Raf (2) Reactive Oxygen Species (2) Somatostatin Receptor (2) STAT (3) Wnt (2) β-catenin (2)
By Research Areas:	Cancer (31) Infection (5) Inflammation/Immunology (3) Metabolic Disease (1)

Targets Recommended: BCRP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0008

Sulindac MK-231	NF-κB PD-1/PD-L1	Inflammation/Immunology Cancer
Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer .

HY-N5014

Liensinine perchlorate Maximum Cited Publications 8 Publications Verification	Apoptosis	Inflammation/Immunology Cancer
Liensinine Perchlorate is a constituent of Nelumbo nucifera Gaertn, with ani-hypertension and anti-cancer activities. Liensinine Perchlorate induces colorectal cancer (CRC) cell apoptosis .

HY-N11777

(−)-N-Hydroxyapiosporamide NHAP	NF-κB	Cancer
(−)-N-Hydroxyapiosporamide (NHAP), an alkaloid, is an NF-κB inhibitor with potent antitumor activity in vitro and in vivo. (−)-N-Hydroxyapiosporamide can be used for the research of colorectal cancer (CRC) .

HY-B0008A

Sulindac sodium MK-231 sodium	NF-κB PD-1/PD-L1	Infection Inflammation/Immunology Cancer
Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer .

HY-151939

BLM-IN-2	DNA/RNA Synthesis Apoptosis	Cancer
BLM-IN-2 is a Bloom's Syndrome Protein (BLM) inhibitor with an IC₅₀ value of 0.8 μM. BLM-IN-2 effectively suppresses the proliferation, invasion, cell cycle arrest and apoptosis of CRC cells. BLM-IN-2 can be used for the reserarch of colorectal cancer (CRC) .

HY-108695

Enterodiol	Apoptosis Endogenous Metabolite	Cancer
Enterodiol is transformed by human intestinal bacteria from lignans contained in various whole-grain cereals, nuts, legumes, flaxseed, and vegetables. Enterodiol has an apoptotic effect in colorectal cancer (CRC) cells. Anti-cancer activities .

HY-153833

PDS-0330 KVA-E-23A	Others	Cancer
PDS-0330 is a specific and potent Claudin-1 inhibitor. PDS-0330 interferes with claudin-1/Src association and inhibits colorectal cancer (CRC) progression and metastasis .

HY-P1201

Cyclosomatostatin	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-W181530

NCT02	CDK	Cancer
NCT02 is a cyclin K degrader. NCT02 induces ubiquitination of cyclin K (CCNK) and proteasomal degradation of CCNK and its complex partner CDK12. NCT02 has the potential for the research of metastatic colorectal cancer (CRC) .

HY-136541

YB-0158 2 Publications Verification Wnt pathway inhibitor 2	Wnt Apoptosis	Cancer
YB-0158 (Wnt pathway inhibitor 2) is a reverse-turn peptidomimetic and a potent colorectal cancer stem cell (CSC) targeting agent. YB-0158 disrupts Sam68-Src interactions and induces apoptosis in CRC cells. Anti-cancer activities .

HY-108695B

(±)-Enterodiol	Apoptosis Endogenous Metabolite	Cancer
(±)-Enterodiol is the racemate of Enterodiol (HY-108695). Enterodiol is transformed by human intestinal bacteria from lignans contained in various whole-grain cereals, nuts, legumes, flaxseed, and vegetables. Enterodiol has an apoptotic effect in colorectal cancer (CRC) cells. Enterodiol has anti-cancer activities .

HY-123772

CDK5 inhibitor 20-223	CDK	Cancer
CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC₅₀s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agent .

HY-160493

PTK7/β-catenin-IN-6	Wnt β-catenin	Cancer
PTK7/β-catenin-IN-6 (Compound 03653) is an inhibitor for PTK7/β-catenin interaction, which inhibits the Wnt signaling pathway, and exhibits an anticancer activity against colorectal cancer (CRC) .

HY-P1201A

Cyclosomatostatin TFA	Somatostatin Receptor	Cancer
Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-N3913

Furowanin A	STAT Bcl-2 Family	Cancer
Furowanin A is a flavonoid with anti-neoplastic effects. Furowanin A inhibits STAT3/Mcl-1 axis to suppress proliferation, block cell cycle progression, induce apoptosis and promote autophagy. Furowanin A potently inhibits colorectal cancer (CRC) cells .

HY-P99406

Petosemtamab MCLA 158	EGFR	Cancer
Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .

HY-114491

Rineterkib	ERK Raf	Cancer
Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .

HY-114491A

Rineterkib hydrochloride	ERK Raf	Cancer
Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .

HY-155068

FC-116	Reactive Oxygen Species Apoptosis Microtubule/Tubulin	Cancer
FC-11 is a Tubulin inhibitor that effectively inhibits tumor growth in mice. FC-11 can also induce endoplasmic reticulum (ER) stress to generate excess reactive oxygen species (ROS), leading to mitochondrial damage, thereby promoting apoptosis in colorectal cancer (CRC) cells by targeting microtubules. FC-11 can be used in cancer research .

HY-146254

hCAIX-IN-12	Carbonic Anhydrase Apoptosis Reactive Oxygen Species	Cancer
hCAIX-IN-12 is a potent hCAIX inhibitor with IC₅₀ values of 0.74, 10.78 µM for CAIX and CAII, respectively. hCAIX-IN-12 shows antiproliferative effect and induces apoptosis. hCAIX-IN-12 increases ROS production. hCAIX-IN-12 has the potential for the research of colorectal cancer (CRC) .

HY-P99613

Favezelimab MK-4280	LAG-3	Cancer
Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902) .

HY-161087

β-catenin/BCL9 PPI-IN-1	β-catenin	Cancer
β-catenin/BCL9 PPI-IN-1 (compound B4) is a potent inhibitor of β catenin/B-Cell lymphoma 9 protein?protein interaction (β catenin/BCL9 PPI) with the IC₅₀ value of 2.25 μM .

HY-161459

GLI1-IN-1	Apoptosis Hedgehog Gli	Cancer
GLI1-IN-1 (CBC-1) is a GLI-1 inhibitor with excellent water solubility and anticancer activity. GLI1-IN-1 can induce apoptosis and suppress the growth of colorectal cancer by inhibiting the Hedgehog(HH) (IC₅₀=1.3 μM) pathway .

HY-108433

CPT2 Carnitine palmitoyltransferase 2	Apoptosis MDM-2/p53	Metabolic Disease Cancer
CPT2 (Carnitine palmitoyltransferase 2), an enzyme that participates in fatty acid oxidation, also is a colorectal cancer (CRC) prognostic biomarker. CPT2 overexpression can activate p-p53 to increase p53 expression, thereby inhibiting tumor proliferation and promoting apoptosis. CPT2 deficiency results in the most common inherited disorder of long-chain fatty acid oxidation affecting skeletal muscle. Downregulation of CPT2 is also highly correlated with the progression of various cancers and has potential for cancer research .

HY-129284

APHS	COX	Cancer
APHS is a specific and covalent COX-2 inhibitor with neuroprotective effects. COX-2 is a prostaglandin (PG) synthetase overexpressed in colorectal cancer (CRC) and has pleiotropic cancer-promoting effects. APHS modifies COX-2 by acetylating the active site (serine 516), thereby inhibiting prostaglandin production. The neuroprotective activity of APHS is inhibited by prostaglandin E2. APHS also co-inhibits the WNT pathway, an anti-tumor mechanism in addition to COX-2 inhibition .

HY-B0294

Flubendazole 5+ Cited Publications	Parasite Microtubule/Tubulin STAT MDM-2/p53 Apoptosis Autophagy	Infection Cancer
Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites .

HY-155491

Antibacterial agent 166	Bacterial	Cancer
Antibacterial agent 166 (Compound 19q), a derivative of Nitisinone (HY-B0607), is a selective and orally active *Fusobacterium nucleatum* inhibitor with a MIC₅₀ of 1 μg/mL. Antibacterial agent 166 effectively attenuates the migratory ability of MC-38 cells induced by Fusobacterium nucleatum. Antibacterial agent 166 is a promising anti-F. nucleatum lead compound and can be used for colorectal cancer (CRC) research .

HY-149558

CXCR4-IN-2	Apoptosis CXCR	Cancer
CXCR4-IN-2 (compound A1) is a bifunctional fluorinated small molecule that is a potent CXCR4 inhibitor with anticancer activity. CXCR4-IN-2 has cytotoxic (IC₅₀: 60 μg/mL; 72 h) and antiproliferative effects on mouse colorectal cancer (CRC) cells. CXCR4-IN-2 induces cell arrest in the G2/M phase and induces apoptosis .

HY-B1324A

Oxiconazole Ro 13-8996 free base	Fungal Cytochrome P450 Antibiotic	Infection Cancer
Oxiconazole (Ro 13-8996) is a broad spectrum anti-fungal agent which can inhibit the growth of Candida, Aspergillus and Trichophyton. Oxiconazole is also a highly efficacious activator of CYP3A4 transactivation, which could be antagonized by Rifampicin (HY-B0272) in a competitive manner. Oxiconazole exhibits inhibitory effect against colorectal cancer (CRC) via peroxiredoxin-2 (PRDX2)-mediated autophagy arrest .

HY-B1324

Oxiconazole nitrate 1 Publications Verification Ro 13-8996	Fungal Cytochrome P450 Antibiotic	Infection Cancer
Oxiconazole (Ro 13-8996) nitrate is a broad spectrum anti-fungal agent which can inhibit the growth of Candida, Aspergillus and Trichophyton. Oxiconazole nitrate is also a highly efficacious activator of CYP3A4 transactivation, which could be antagonized by Rifampicin (HY-B0272) in a competitive manner. Oxiconazole nitrate exhibits inhibitory effect against colorectal cancer (CRC) via peroxiredoxin-2 (PRDX2)-mediated autophagy arrest .

HY-N8146

Bruceantinol	STAT	Infection Cancer
Bruceantinol, a quassinoid isolated from Brucea javanica, inhibits pepper mottle virus in pepper . Bruceantinol is a STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models. Bruceantinol strongly inhibits STAT3 DNA-binding ability (IC₅₀=2.4 pM), blocks the constitutive and IL-6-induced STAT3 activation, and suppresses transcription of MCL-1, PTTG1, survivin and c-Myc .

HY-N2187

Deoxyshikonin 1 Publications Verification
Deoxyshikonin increases the expression of VEGF-C and VEGF-A mRNA in HMVEC-dLy, promotes HIF-1α and HIF-1β subunit interaction and binds to specific DNA sequences targeted by HIF. Deoxyshikonin inhibited colorectal cancer (CRC) through the PI3K/Akt/mTOR pathway. Deoxyshikonin has proangiogenesis effect and antitumor activity. Deoxyshikonin is an antibacterial agent against methicillin-resistant S. aureus (MRSA) and S. pneumonia (MIC=17 μg/mL) .

Cat. No.	Product Name

HY-L103

Anti-Colorectal Cancer Compound Library	1618 compounds
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer. Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1618 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Anti-Colorectal Cancer Compound Library

1618 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1618 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-114491

Rineterkib	Fluorescent Dyes/Probes
Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .

Rineterkib

Fluorescent Dyes/Probes

Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .

Cat. No.	Product Name	Type

HY-108433

CPT2 Carnitine palmitoyltransferase 2	Biochemical Assay Reagents
CPT2 (Carnitine palmitoyltransferase 2), an enzyme that participates in fatty acid oxidation, also is a colorectal cancer (CRC) prognostic biomarker. CPT2 overexpression can activate p-p53 to increase p53 expression, thereby inhibiting tumor proliferation and promoting apoptosis. CPT2 deficiency results in the most common inherited disorder of long-chain fatty acid oxidation affecting skeletal muscle. Downregulation of CPT2 is also highly correlated with the progression of various cancers and has potential for cancer research .

CPT2

Carnitine palmitoyltransferase 2

Biochemical Assay Reagents

CPT2 (Carnitine palmitoyltransferase 2), an enzyme that participates in fatty acid oxidation, also is a colorectal cancer (CRC) prognostic biomarker. CPT2 overexpression can activate p-p53 to increase p53 expression, thereby inhibiting tumor proliferation and promoting apoptosis. CPT2 deficiency results in the most common inherited disorder of long-chain fatty acid oxidation affecting skeletal muscle. Downregulation of CPT2 is also highly correlated with the progression of various cancers and has potential for cancer research .

Cat. No.	Product Name	Target	Research Area

HY-P1201

Cyclosomatostatin	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-P1201A

Cyclosomatostatin TFA	Somatostatin Receptor	Cancer
Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

Cat. No.	Product Name	Target	Research Area

HY-P99406

Petosemtamab MCLA 158	EGFR	Cancer
Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .

HY-P99613

Favezelimab MK-4280	LAG-3	Cancer
Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N5014

Liensinine perchlorate 5+ Cited Publications	Alkaloids other families Classification of Application Fields Source classification Phenols Polyphenols Plants Isoquinoline Alkaloids Disease Research Fields Inflammation/Immunology	Apoptosis
Liensinine Perchlorate is a constituent of Nelumbo nucifera Gaertn, with ani-hypertension and anti-cancer activities. Liensinine Perchlorate induces colorectal cancer (CRC) cell apoptosis .

HY-N11777

(−)-N-Hydroxyapiosporamide NHAP	Structural Classification Alkaloids Microorganisms Source classification Pyridine Alkaloids	NF-κB
(−)-N-Hydroxyapiosporamide (NHAP), an alkaloid, is an NF-κB inhibitor with potent antitumor activity in vitro and in vivo. (−)-N-Hydroxyapiosporamide can be used for the research of colorectal cancer (CRC) .

HY-108695

Enterodiol	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Source classification Phenols Polyphenols Endogenous metabolite Disease Research Fields Cancer	Apoptosis Endogenous Metabolite
Enterodiol is transformed by human intestinal bacteria from lignans contained in various whole-grain cereals, nuts, legumes, flaxseed, and vegetables. Enterodiol has an apoptotic effect in colorectal cancer (CRC) cells. Anti-cancer activities .

HY-108695B

(±)-Enterodiol	Structural Classification Source classification Phenols Polyphenols Endogenous metabolite	Apoptosis Endogenous Metabolite
(±)-Enterodiol is the racemate of Enterodiol (HY-108695). Enterodiol is transformed by human intestinal bacteria from lignans contained in various whole-grain cereals, nuts, legumes, flaxseed, and vegetables. Enterodiol has an apoptotic effect in colorectal cancer (CRC) cells. Enterodiol has anti-cancer activities .

HY-N3913

Furowanin A	Structural Classification Flavonoids Leguminosae Source classification Plants Derris taiwaniana (Hayata) Z. Q. Song Isoflavones	STAT Bcl-2 Family
Furowanin A is a flavonoid with anti-neoplastic effects. Furowanin A inhibits STAT3/Mcl-1 axis to suppress proliferation, block cell cycle progression, induce apoptosis and promote autophagy. Furowanin A potently inhibits colorectal cancer (CRC) cells .

HY-N8146

Bruceantinol	Infection Triterpenes Simaroubaceae Classification of Application Fields Brucea antidysenterica J.F.Mill. Terpenoids Source classification Plants Disease Research Fields Cancer Brucea javanica (L.) Merr.	STAT
Bruceantinol, a quassinoid isolated from Brucea javanica, inhibits pepper mottle virus in pepper . Bruceantinol is a STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models. Bruceantinol strongly inhibits STAT3 DNA-binding ability (IC₅₀=2.4 pM), blocks the constitutive and IL-6-induced STAT3 activation, and suppresses transcription of MCL-1, PTTG1, survivin and c-Myc .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

colorectal cancer (CRC)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Natural
Products